LifeSci Capital initiated coverage of Zymeworks (ZYME) with an Outperform rating and $30 price target
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZYME:
- Zymeworks: Hold Rating Amid Financial Challenges and Upcoming Catalysts
- Zymeworks price target raised to $13 from $12 at H.C. Wainwright
- Zymeworks price target raised to $19 from $18 at Citi
- Zymeworks: Promising Pipeline and Financial Stability Justify Buy Rating
- Zymeworks Faces Challenges in Diagnostic Test Development Amidst Regulatory Changes